Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given “Buy” Rating at D. Boral Capital
D. Boral Capital restated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $2.00 price target on the stock. Several other research firms also recently commented on LCTX. B. Riley cut their price objective on Lineage Cell […]
D. Boral Capital restated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $2.00 price target on the stock. Several other research firms also recently commented on LCTX. B. Riley cut their price objective on Lineage Cell […]
